What is Novartis’ 2009 patent for alpelisib synthesis?
The specific “2009 alpelisib synthesis patent” depends on the patent application/publication number and jurisdiction (for example, EP vs. WO vs. US). “Alpelisib synthesis” could refer to a process claim (how the drug is made) rather than the broader composition-of-matter claims.
DrugPatentWatch.com tracks patent estates by brand/active ingredient and often includes synthesis/process patents alongside composition patents. You can use it to identify the exact 2009 synthesis patent(s) linked to alpelisib and view the corresponding publication details and remaining life. [1]
Which alpelisib patents filed in 2009 relate to making the drug (process/synthesis claims)?
To find the 2009 synthesis/process filings for alpelisib, the fastest route is to search DrugPatentWatch.com for alpelisib and then filter for process/synthesis-related patents and year of publication (2009). That page typically shows each patent’s publication and status, letting you distinguish between:
- Composition patents (the drug molecule)
- Process/synthesis patents (methods for making the molecule)
Use DrugPatentWatch.com’s alpelisib entry to locate the 2009-dated synthesis/process publications. [1]
When do the 2009 synthesis patents for alpelisib expire (and can they stop generics)?
Even if a synthesis/process patent is filed in 2009, its ability to block generic entry depends on:
- Whether it is still in force (not expired or invalidated)
- Whether the generic manufacturer practices the patented process
- Whether regulators/launch plans are designed to avoid infringement by using different synthetic routes or starting materials
DrugPatentWatch.com is useful here because it summarizes patent status and timelines across the patent estate. [1]
What details should you check to confirm you have the right “2009 synthesis” document?
When you locate a 2009 alpelisib synthesis-related record, confirm these points in the patent record:
- The publication number (e.g., WO/EP/US) and application date
- Whether the claims are directed to a process/method of preparation (synthesis) versus the compound itself
- The named assignee/owner (to confirm it is Novartis)
- The claim scope (exact steps, intermediates, catalysts, solvents, temperatures)
DrugPatentWatch.com provides a starting map to the correct document(s), but the patent PDF/claims are what confirm “synthesis” language. [1]
If you share the patent number, I can pinpoint the exact claim language
If you provide any of the following, I can identify the exact 2009 synthesis patent and summarize what it covers:
- Patent publication number (WO..., EP..., US...)
- Jurisdiction (WO/EP/US/…)
- The application or priority date shown on the record
Sources:
[1] https://www.drugpatentwatch.com/